AgeneBio CEO Michela Gallagher and Vice President of Research and Development Sharon Rosenzweig-Lipson Present at Biomarkers for Alzheimer’s Disease 2021

Integrating Biomarkers into Trial Design, Patient Selection & Outcome Measures: AgeneBio’s The Hope4MCI Trial